more

Amgen (AMGN)

(Delayed Data from NSDQ)

$305.85 USD

+4.85 (1.61%)

Updated May 31, 2024 04:00 PM ET

After-Market: $305.50 -0.35 (-0.11%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	24.08%
2	Buy	17.91%
3	Hold	9.44%
4	Sell	5.10%
5	Strong Sell	2.55%
S&P	500	11.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5 3

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth C Momentum D VGM

Industry Rank:

Top 38% (95 out of 250)

Industry: Medical - Biomedical and Genetics

View All Zacks #1 Ranked Stocks

Better trading starts here.

Research for AMGN

Annual Key Company Metrics
Quarterly Key Company Metrics

Revenue - Line of Business Segments	YR Estimate	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019
Product Sales: Aimovig: Total [$M...		323	414	317	378	306
Product Sales: EVENITY: Total [$M...		1,160	787	530	350	189
Product Sales: Otezla: Total [$M]		2,188	2,288	2,249	2,195	178
Product Sales: AMJEVITA/AMGEVITA:...		626	460	439	331	215
Product Sales: MVASI: Total [$M]		800	901	1,166	798	127
Product Sales: KANJINTI: Total [$...	--	159	316	572	567	226
Product Sales: TEZSPIRE: Total [$...		567	170	0	--	--
Revenue: Product: TAVNEOS: Total ...		134	21	0	--	--
Revenue: Product sales [$M]		26,910	24,801	24,297	24,240	22,204
Product Sales: Neulasta: Total [$...		848	1,126	1,734	2,293	3,221
Revenue: Other revenues [$M]		5,263	5,220	5,321	5,724	5,538
Product Sales: Other products: To...		175	160	339	283	312
Product Sales: EPOGEN: Total [$M]		226	506	521	598	867
Product Sales: Aranesp: Total [$M...		1,362	1,421	1,480	1,568	1,729
Product Sales: Prolia: Total [$M]		4,048	3,628	3,248	2,763	2,672
Product Sales: Repatha: Total [$M...		1,635	1,296	1,117	887	661
Product Sales: Parsabiv: Total [$...		362	382	280	716	630
Product Sales: KYPROLIS: Total [$...		1,403	1,247	1,108	1,065	1,044
Product Sales: XGEVA: Total [$M]		2,112	2,014	2,018	1,899	1,935
Product Sales: Vectibix: Total [$...		984	893	873	811	744
Product Sales: Nplate: Total [$M]		1,477	1,307	1,027	850	795
Product Sales: BLINCYTO: Total [$...		861	583	472	379	312
Product Sales: Enbrel: Total [$M]		3,697	4,117	4,465	4,996	5,226
Product Sales: LUMAKRAS/LUMYKRAS:...		280	285	90	0	--
Revenue - Geographic Segments	YR Estimate	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019
Product Sales: BLINCYTO: US [$M]		566	336	278	231	176
Product Sales: BLINCYTO: ROW [$M]		295	247	194	148	136
Product Sales: Aimovig: US [$M]		303	398	313	378	306
Product Sales: Aimovig: ROW [$M]		20	16	4	0	0
Product Sales: EVENITY: US [$M]		809	533	331	191	42
Product Sales: EVENITY: ROW [$M]		351	254	199	159	147
Product Sales: Otezla: US [$M]		1,777	1,886	1,804	1,790	139
Product Sales: Otezla: ROW [$M]		411	402	445	405	39
Product Sales: MVASI: US [$M]		511	602	826	656	121
Product Sales: MVASI: ROW [$M]		289	299	340	142	6
Product Sales: KANJINTI: US [$M]	--	109	257	479	475	118
Product Sales: KANJINTI: ROW [$M]	--	50	59	93	92	108
Product Sales: AMJEVITA/AMGEVITA:...		126	0	0	0	0
Product Sales: AMJEVITA/AMGEVITA:...		500	460	439	331	215
Product Sales: LUMAKRAS/LUMYKRAS:...		197	222	82	--	--
Product Sales: LUMAKRAS/LUMYKRAS:...		83	63	8	--	--
Revenue: Product: TAVNEOS: US [$M...		126	16	0	--	--
Revenue: Product: TAVNEOS: ROW [$...		8	5	0	--	--
Product Sales: Aranesp: US [$M]		452	521	537	629	758
Product Sales: Aranesp: ROW [$M]		910	900	943	939	971
Product Sales:Enbrel: US [$M]		3,650	4,044	4,352	4,855	5,050
Product Sales: Enbrel: ROW [$M]		47	73	113	141	176
Product Sales: Neulasta: US [$M]		710	959	1,514	2,001	2,814
Product Sales: Neulasta: ROW [$M]		138	167	220	292	407
Product Sales: Vectibix: US [$M]		461	396	347	342	316
Product Sales: Vectibix: ROW [$M]		523	497	526	469	428
Revenue: Product: Other: US [$M]		576	393	202	109	105
Revenue: Product: Other: Internat...		160	246	137	174	207
Product Sales: EPOGEN: US [$M]		226	506	521	598	867
Product Sales: Nplate: US [$M]		996	848	566	485	480
Product Sales: Nplate: ROW [$M]		481	459	461	365	315
Revenue: Product: International [...		7,638	7,058	7,011	6,255	5,673
Revenue: Product: US [$M]		19,272	17,743	17,286	17,985	16,531
Product Sales: Prolia: US [$M]		2,733	2,465	2,150	1,830	1,772
Product Sales: Prolia: ROW [$M]		1,315	1,163	1,098	933	900
Product Sales: Repatha: US [$M]		793	608	557	459	376
Product Sales: Repatha: ROW [$M]		842	688	560	428	285
Product Sales: Parsabiv: US [$M]		228	253	150	605	550
Product Sales: Parsabiv: ROW [$M]		134	129	130	111	80
Product Sales: KYPROLIS: US [$M]		921	850	736	710	654
Product Sales: KYPROLIS: ROW [$M]		482	397	372	355	390
Product Sales: XGEVA: US [$M]		1,527	1,480	1,434	1,405	1,457
Product Sales: XGEVA: ROW [$M]		585	534	584	494	478

Revenue - Line of Business Segments	Qtr Estimate	03/31/2024	12/31/2023	09/30/2023	06/30/2023	03/31/2023
Product Sales: Aimovig: Total [$M...		65	78	94	82	64
Product Sales: EVENITY: Total [$M...		342	318	307	281	254
Product Sales: Otezla: Total [$M]		394	629	567	600	392
Product Sales: AMJEVITA/AMGEVITA:...		168	160	152	150	164
Product Sales: MVASI: Total [$M]		202	188	213	197	202
Product Sales: KANJINTI: Total [$...	--	--	42	20	50	47
Product Sales: TEZSPIRE: Total [$...		173	177	161	133	96
Revenue: Product: TAVNEOS: Total ...		51	44	37	30	23
Revenue: Product sales [$M]		7,118	7,833	6,548	6,683	5,846
Product Sales: Neulasta: Total [$...		118	239	124	236	249
Revenue: Other revenues [$M]		329	363	355	303	259
Product Sales: Other products: To...		357	175	167	174	309
Product Sales: EPOGEN: Total [$M]		41	55	50	61	60
Product Sales: Aranesp: Total [$M...		349	319	323	365	355
Product Sales: Prolia: Total [$M]		999	1,107	986	1,028	927
Product Sales: Repatha: Total [$M...		517	417	406	424	388
Product Sales: Parsabiv: Total [$...		105	89	95	87	91
Product Sales: KYPROLIS: Total [$...		376	350	349	346	358
Product Sales: XGEVA: Total [$M]		561	527	519	530	536
Product Sales: Vectibix: Total [$...		247	251	252	248	233
Product Sales: Nplate: Total [$M]		317	386	419	310	362
Product Sales: BLINCYTO: Total [$...	--	244	241	220	206	194
Product Sales: Enbrel: Total [$M]		567	1,015	1,035	1,068	579
Product Sales: LUMAKRAS/LUMYKRAS:...		82	77	52	77	74
Revenue - Geographic Segments	Qtr Estimate	03/31/2024	12/31/2023	09/30/2023	06/30/2023	03/31/2023
Product Sales: BLINCYTO: US [$M]		153	148	147	145	126
Product Sales: BLINCYTO: ROW [$M]		91	93	73	61	68
Product Sales: Aimovig: US [$M]		65	73	88	78	64
Product Sales: Aimovig: ROW [$M]		5	5	6	4	5
Product Sales: EVENITY: US [$M]		236	239	214	192	164
Product Sales: EVENITY: ROW [$M]		106	79	93	89	90
Product Sales: Otezla: US [$M]		293	526	462	495	294
Product Sales: Otezla: ROW [$M]		101	103	105	105	98
Product Sales: MVASI: US [$M]		105	127	140	123	121
Product Sales: MVASI: ROW [$M]		97	61	73	74	81
Product Sales: KANJINTI: US [$M]	--	--	31	7	38	33
Product Sales: KANJINTI: ROW [$M]	--	--	11	13	12	14
Product Sales: AMJEVITA/AMGEVITA:...		30	33	23	19	51
Product Sales: AMJEVITA/AMGEVITA:...		138	127	129	131	113
Product Sales: LUMAKRAS/LUMYKRAS:...		53	51	48	50	48
Product Sales: LUMAKRAS/LUMYKRAS:...		29	26	4	27	26
Revenue: Product: TAVNEOS: US [$M...		45	42	32	29	23
Revenue: Product: TAVNEOS: ROW [$...		6	2	5	1	0
Product Sales: Aranesp: US [$M]		100	107	107	123	115
Product Sales: Aranesp: ROW [$M]		249	212	216	242	240
Product Sales:Enbrel: US [$M]		561	1,005	1,026	1,055	564
Product Sales: Enbrel: ROW [$M]		6	10	9	13	15
Product Sales: Neulasta: US [$M]		87	208	92	199	211
Product Sales: Neulasta: ROW [$M]		31	31	32	37	38
Product Sales: Vectibix: US [$M]		120	116	116	118	111
Product Sales: Vectibix: ROW [$M]		127	135	136	130	122
Revenue: Product: Other: US [$M]		261	137	136	124	185
Revenue: Product: Other: Internat...		51	38	31	50	55
Product Sales: EPOGEN: US [$M]		41	55	50	61	60
Product Sales: Nplate: US [$M]		190	252	322	176	246
Product Sales: Nplate: ROW [$M]		127	134	97	134	116
Revenue: Product: International [...		2,145	1,963	1,857	1,947	1,871
Revenue: Product: US [$M]		4,973	5,870	4,691	4,736	3,975
Product Sales: Prolia: US [$M]		657	746	673	691	623
Product Sales: Prolia: ROW [$M]		342	361	313	337	304
Product Sales: Repatha: US [$M]		273	201	183	212	197
Product Sales: Repatha: ROW [$M]		244	216	223	212	191
Product Sales: Parsabiv: US [$M]		65	57	59	54	58
Product Sales: Parsabiv: ROW [$M]		40	32	36	33	33
Product Sales: KYPROLIS: US [$M]		234	222	231	234	234
Product Sales: KYPROLIS: ROW [$M]		142	128	118	112	124
Product Sales: XGEVA: US [$M]		366	382	374	387	384
Product Sales: XGEVA: ROW [$M]		195	145	145	143	152

Member Sign In

Member Sign In

Services Overview

Investor Services

Other Services

Trading Services

Innovators